```
  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:21:06 ON 21 DEC 2005

=> fil reg
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILE 'REGISTRY' ENTERED AT 11:21:18 ON 21 DEC 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   19 DEC 2005  HIGHEST RN 870234-75-6
DICTIONARY FILE UPDATES:  19 DEC 2005  HIGHEST RN 870234-75-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

*************************************************************************
*                                                                       *
* The CA roles and document type information have been removed from     *
* the IDE default display format and the ED field has been added,       *
* effective March 20, 2005.  A new display format, IDERL, is now        *
* available and contains the CA role and document type information.     *
*                                                                       *
*************************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10727168Amend.str
```





chain nodes :
14 15 16
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12
chain bonds :
9-14 10-15 11-16
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-12 7-8 8-9 9-10 10-11 11-12
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-12 7-8 8-9 9-10 9-14 10-11 10-15 11-12 11-16

G1:C,N

G2:Ak,H

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 14:CLASS 15:CLASS 16:CLASS 17:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 C,N
G2 Ak,H

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 11:21:38 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 11111 TO ITERATE

18.0% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

```
PROJECTED ITERATIONS:       215904 TO   228536
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 11:21:43 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   220660 TO ITERATE

100.0% PROCESSED   220660 ITERATIONS                              33 ANSWERS
SEARCH TIME: 00.00.03

L3           33 SEA SSS FUL L1

=> fil hcaplus
COST IN U.S. DOLLARS                              SINCE FILE      TOTAL
                                                     ENTRY    SESSION
FULL ESTIMATED COST                                 161.33     161.54

FILE 'HCAPLUS' ENTERED AT 11:22:00 ON 21 DEC 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 21 Dec 2005  VOL 143 ISS 26
FILE LAST UPDATED: 20 Dec 2005  (20051220/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> s l3
L4            7 L3

=> d ed abs ibib hitstr 1-7
```

L4 ANSWER 1 OF 7 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 25 Jun 2004
GI



I II

III

AB Title compds. I [A = C-X, N; B = C-Y, N; R1 = H, alkyl; R2 = H, alkyl; X = H, OH, CONH2, etc.; Y = H, OH, NH2, etc.; Z = H, OH, F, etc.] their enantiomers and pharmaceutically acceptable salts were prepared For example, BH3-THF reduction of lactam II, e.g., prepared from 3-methoxybenzaldehyde in 5-steps, afforded 2-phenylmorpholine III in 84% yield. Compds. I expressed EC50 values < 1000 nM with 10-fold selectivity for D3 over D2, e.g., one example of compound I exhibited an EC50 value of 7.6 nM and 1315.8 fold selectivity for D3 over D2. Compds. I are claimed useful for the treatment of sexual dysfunction, e.g., hypoactive sexual activity, orgasmic disorders, erectile dysfunction, etc.

ACCESSION NUMBER: 2004:513545 HCAPLUS
DOCUMENT NUMBER: 141:71567
TITLE: Preparation of 2-phenylmorpholines and related compounds as dopamine agonists in the treatment of sexual dysfunction.
INVENTOR(S): Allerton, Charlotte Maria Norfor; Baxter, Andrew Douglas; Cook, Andrew Simon; Hepworth, David; Wong, Stephen Kwok-fung
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: PCT Int. Appl., 121 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004052372	A1	20040624	WO 2003-IB5683	20031202

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

L4 ANSWER 1 OF 7 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2508262	AA	20040624	CA 2003-2508262	20031202
US 2004259874	A1	20041223	US 2003-727168	20031202
EP 1572214	A1	20050914	EP 2003-812639	20031202

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

BR 2003017102	A	20051025	BR 2003-17102	20031202
NL 1024983	A1	20040611	NL 2003-1024983	20031210
NL 1024983	C2	20050201		
NO 2005002557	A	20050906	NO 2005-2557	20050526

PRIORITY APPLN. INFO.:

GB 2002-28787	A	20021210
GB 2003-8460	A	20030411
GB 2003-13606	A	20030612
US 2003-438476P	P	20030107
US 2003-470950P	P	20030515
US 2003-501512P	P	20030908
WO 2003-IB5683	W	20031202

Appl.

OTHER SOURCE(S): MARPAT 141:71567
IT 547770-39-8P, 6-[6-(2,5-Dimethylpyrrol-1-yl)pyridin-3-yl]-4-propylmorpholine
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 2-phenylmorpholines and related compds. as dopamine agonists in the treatment of sexual dysfunction.)
RN 547770-39-8 HCAPLUS
CN Morpholine, 2-[6-(2,5-dimethyl-1H-pyrrol-1-yl)-3-pyridinyl]-4-propyl- (9CI) (CA INDEX NAME)



IT 710653-32-0P, 5-(4-Propylmorpholin-2-yl)pyridin-2-ylamine
710653-37-5P 710653-43-3P 710655-10-0P
710655-15-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

L4 ANSWER 1 OF 7 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(prepn. of 2-phenylmorpholines and related compds. as dopamine agonists in the treatment of sexual dysfunction.)
RN 710653-32-0 HCAPLUS
CN 2-Pyridinamine, 5-(4-propyl-2-morpholinyl)- (9CI) (CA INDEX NAME)



RN 710653-37-5 HCAPLUS
CN 2-Pyridinamine, 5-(4-propyl-2-morpholinyl)-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 710653-43-3 HCAPLUS
CN 2-Pyridinamine, 5-(4-propyl-2-morpholinyl)-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 710655-10-0 HCAPLUS
CN 2-Pyridinamine, 5-[(2S,5S)-5-methyl-4-propyl-2-morpholinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 710655-15-5 HCAPLUS
CN 2-Pyridinamine, 5-[(2R,5S)-5-methyl-4-propyl-2-morpholinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 7 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Absolute stereochemistry. Rotation (+).



IT 710654-89-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 2-phenylmorpholines and related compds. as dopamine agonists in the treatment of sexual dysfunction.)
RN 710654-89-0 HCAPLUS
CN 2-Morpholinol, 2-[6-(2,5-dimethyl-1H-pyrrol-1-yl)-3-pyridinyl]-5-methyl-4-propyl-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 2 OF 7 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 27 Jun 2003
AB The use of a composition comprising a selective dopamine D3 receptor agonist is disclosed, wherein said dopamine D3 receptor agonist is at least about 15-times more functionally selective for a dopamine D3 receptor as compared with a dopamine D2 receptor when measured using the same functional assay, in the preparation of a medicament for the treatment and/or prevention of sexual dysfunction.
ACCESSION NUMBER: 2003:491050 HCAPLUS
DOCUMENT NUMBER: 139:63348
TITLE: Selective dopamine D3 receptor agonists for the treatment of sexual dysfunction
INVENTOR(S): Van der Graaf, Pieter Hadewijn; Wayman, Christopher Peter; Baxter, Andrew Douglas; Cook, Andrew Simon; Wong, Stephen Kwok-Fung
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: PCT Int. Appl., 247 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003051370	A1	20030626	WO 2002-GB5595	20021210
WO 2003051370	C1	20031002		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2470624	AA	20030626	CA 2002-2470624	20021210
EP 1463508	A1	20041006	EP 2002-788092	20021210
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002015064	A	20041013	BR 2002-15064	20021210
JP 2005516014	T2	20050602	JP 2003-552303	20021210
ZA 2004003906	A	20050622	ZA 2004-3906	20040520

PRIORITY APPLN. INFO.: GB 2001-30219 A 20011218
WO 2002-GB5595 W 20021210

IT 547770-39-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(selective dopamine D3 receptor agonists for the treatment of sexual dysfunction)
RN 547770-39-8 HCAPLUS
CN Morpholine, 2-[6-(2,5-dimethyl-1H-pyrrol-1-yl)-3-pyridinyl]-4-propyl- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 7 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 7 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 12 Jan 2003
AB A potent and selective sulfonamide β3 agonist with an excellent pharmacokinetic profile has recently been synthesized. During the anal. by liquid chromatog./tandem mass spectrometry (LC/MS/MS) of metabolites of the sulfonamide N-{4-[2-(2-hydroxy-2-pyridin-3-ylethylamino)ethyl]phenyl}-4-[4-(4-trifluoromethylphenyl)thiazol-2-yl]benzsulfonamide (compound A), we observed loss of 64 Da for a few of the metabolites in the neg. ion mode. Accurate mass measurements performed with Fourier transform ion cyclotron resonance (FTICR) mass spectrometry and quadrupole time-of-flight (Q-TOF) mass spectrometry suggested that the loss of 64 Da corresponded to the loss of SO2. The same phenomenon was observed for a group of structurally related and com. available compds. that also contain a sulfonamide moiety. MS/MS anal. of the fragment ions that had lost SO2 in the ion source suggested that these ions were covalently bound rather than ion-mol. complexes. The neutral loss involving the cleavage of two bonds was unanticipated and suggested a complex rearrangement process. A mechanism for the loss of SO2 has been proposed.
ACCESSION NUMBER: 2003:24118 HCAPLUS
DOCUMENT NUMBER: 139:185456
TITLE: The unanticipated loss of SO2 from sulfonamides in collision-induced dissociation
AUTHOR(S): Wang, Zhen; Hop, Cornelis E. C. A.; Kim, Mi-Sook; Huskey, Su-E. W.; Baillie, Thomas A.; Guan, Ziqiang
CORPORATE SOURCE: Department of Drug Metabolism, Merck Research Laboratories, Rahway, NJ, 07065-0900, USA
SOURCE: Rapid Communications in Mass Spectrometry (2003), 17(1), 81-86
CODEN: RCMSEF; ISSN: 0951-4198
PUBLISHER: John Wiley & Sons Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 579489-11-5
RL: ANT (Analyte); ANST (Analytical study)
(mass spectrometry and unanticipated loss of SO2 from sulfonamides in collision-induced dissociation)
RN 579489-11-5 HCAPLUS
CN Benzenesulfonamide, N-[4-[2-[2-(3-pyridinyl)-4-morpholinyl]ethyl]phenyl]-4-[4-[4-(trifluoromethyl)phenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 7 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 07 Jul 2002
AB The pharmacokinetics and oral bioavailability of (R)-N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-[4-(trifluoromethylphenyl)]thiazol-2-yl]benzenesulfonamide (1), a 3-pyridyl thiazole benzenesulfonamide β3-adrenergic receptor agonist, were investigated in rats, dogs, and monkeys. Systemic clearance was higher in rats (.apprx.30 mL/min/kg) than in dogs and monkeys (both .apprx.10 mL/min/kg), and oral bioavailability was 17, 27, and 4%, resp. Since systemic clearance was 25 to 40% of hepatic blood flow in these species, hepatic extraction was expected to be low, and it was likely that oral bioavailability was limited either by absorption or a large first-pass effect in the gut. The absorption and excretion of 3H-labeled 1 were investigated in rats, and only 28% of the administered radioactivity was orally absorbed. Subsequently, the hepatic extraction of 1 was evaluated in rats (30%) and monkeys (47%). The low oral bioavailability in rats could be explained completely by poor oral absorption and hepatic first-pass metabolism; in monkeys, oral absorption was either less than in rats or first-pass extraction in the gut was greater. In an attempt to increase oral exposure, the pharmacokinetics and oral bioavailability of two potential prodrugs of 1, an N-Et [(R)-N-[4-[2-[ethyl[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-[4-[4-(trifluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide; 2] and a morpholine derivative [(R)-N-[4-[2-[2-(3-pyridinyl)morpholin-4-yl]ethyl]phenyl]-4-[4-[4-(trifluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide; 3], were evaluated in monkeys. Conversion to 1 was low (<3%) with both derivs., and neither entity was an effective prodrug, but the oral bioavailability of 3 (56%) compared with 1 (4%) was significantly improved. The hypothesis that the increased oral bioavailability of 3 was due to a reduction in hydrogen bonding sites in the mol. led to the design of (R)-N-[4-[2-[[2-hydroxy-2-(pyridin-2-yl)ethyl]amino]ethyl]phenyl]-4-[4-(4-trifluoromethylphenyl)thiazol-2-yl]benzenesulfonamide (4), a 2-pyridyl β3-adrenergic receptor agonist with improved oral bioavailability in rats and monkeys.
ACCESSION NUMBER: 2002:505888 HCAPLUS
DOCUMENT NUMBER: 138:49353
TITLE: The pharmacokinetics of a thiazole benzenesulfonamide β3-adrenergic receptor agonist and its analogs in rats, dogs, and monkeys: improving oral bioavailability
AUTHOR(S): Stearns, Ralph A.; Miller, Randy R.; Tang, Wei; Kwei, Gloria Y.; Tang, Frank S.; Mathvink, Robert J.; Naylor, Elizabeth M.; Chitty, Dawn; Colandrea, Vincent J.; Weber, Ann E.; Colletti, Adria E.; Strauss, John R.; Keohane, Carol Ann; Feeney, William P.; Iliff, Susan A.; Chiu, Shuet-Hing Lee
CORPORATE SOURCE: Department of Drug Metabolism, Merck Research Laboratories, Rahway, NJ, USA
SOURCE: Drug Metabolism and Disposition (2002), 30(7), 771-777
CODEN: DMDSAI; ISSN: 0090-9556
PUBLISHER: American Society for Pharmacology and Experimental Therapeutics
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 479092-31-4
RL: BSU (Biological study, unclassified); PKT (Pharmacokinetics); BIOL (Biological study)
(pharmacokinetics of a thiazole benzenesulfonamide β3-adrenergic receptor agonist and its analogs in rats, dogs, and monkeys)
RN 479092-31-4 HCAPLUS
CN Benzenesulfonamide, N-[4-[2-[(2R)-2-(3-pyridinyl)-4-morpholinyl]ethyl]phenyl]-4-[4-[4-(trifluoromethyl)phenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 7 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 7 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 31 May 1992
GI



I II III

AB Morpholine derivs. I [R = alkyl, cycloalkyl, (substituted) aralkyl, heterocyclylalkyl, etc.; R1 = (substituted) pyridyl, tetrazolopyridyl, etc.] are prepared Cyclization of 5.6 g amino alc. II with ClCH2COCl in CH2Cl2 gave 2.16 g oxomorpholine derivative III (X = O), which (2.09 g) was reduced with BH3-Me2S in THF under N to give 1.99 g morpholine derivative III (X = 2 H) (IV). Reduction of 1.66 g IV with SnCl2.2H2O-HCl in MeOH gave 1.39 g I (R = Me3C, R1 = 6-amino-3-pyridyl), which was converted to its citrate salt. The daily doses of I were 0.01-1.0 mg/kg as animal growth promoters, 2-150 mg as bronchodilators, 200-1000 mg as antidepressants and antiobesity agents.

ACCESSION NUMBER: 1992:214513 HCAPLUS
DOCUMENT NUMBER: 116:214513
TITLE: Preparation of morpholine derivatives as animal growth promoters, bronchodilators, antidepressants, and antiobesity agents
INVENTOR(S): Fisher, Michael H.; Wyvratt, Matthew J.
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: U.S., 10 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5077290	A	19911231	US 1990-597976	19901011
US 5124328	A	19920623	US 1991-767285	19910926

PRIORITY APPLN. INFO.: US 1990-597976 A3 19901011
OTHER SOURCE(S): MARPAT 116:214513
IT 140690-61-5P 140690-65-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reduction of, in preparation of morpholine compound)
RN 140690-61-5 HCAPLUS
CN Tetrazolo[1,5-a]pyridine, 6-[4-(1,1-dimethylethyl)-2-morpholinyl]- (9CI)

L4 ANSWER 5 OF 7 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(CA INDEX NAME)



RN 140690-65-9 HCAPLUS
CN Tetrazolo[1,5-a]pyridine, 8-chloro-6-[4-(1,1-dimethylethyl)-2-morpholinyl]- (9CI) (CA INDEX NAME)



IT 140690-67-1P 140690-68-2P 140690-69-3P
140690-70-6P 140690-71-7P 140690-72-8P
140690-73-9P 140690-74-0P 140690-75-1P
140690-76-2P 140690-77-3P 140690-78-4P
140690-79-5P 141137-41-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as drug and animal growth promoter)
RN 140690-67-1 HCAPLUS
CN 2-Pyridinamine, 5-[4-(1,1-dimethylethyl)-2-morpholinyl]-, 2-hydroxy-1,2,3-propanetricarboxylate (9CI) (CA INDEX NAME)

CM 1

CRN 140690-66-0
CMF C13 H21 N3 O



CM 2

CRN 77-92-9
CMF C6 H8 O7

L4 ANSWER 5 OF 7 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 140690-68-2 HCAPLUS
CN 2-Pyridinamine, 5-[4-(1-methyl-3-phenylpropyl)-2-morpholinyl]- (9CI) (CA INDEX NAME)



RN 140690-69-3 HCAPLUS
CN 2-Pyridinamine, 5-[4-(1,1-dimethyl-3-phenylpropyl)-2-morpholinyl]- (9CI) (CA INDEX NAME)



RN 140690-70-6 HCAPLUS
CN 2-Pyridinamine, 5-[4-[3-(3-methoxyphenyl)-1,1-dimethylpropyl]-2-morpholinyl]- (9CI) (CA INDEX NAME)



RN 140690-71-7 HCAPLUS
CN Phenol, 4-[3-[2-(6-amino-3-pyridinyl)-4-morpholinyl]-3-methylbutyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 7 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 140690-72-8 HCAPLUS
CN Phenol, 3-[3-[2-(6-amino-3-pyridinyl)-4-morpholinyl]-3-methylbutyl]- (9CI) (CA INDEX NAME)



RN 140690-73-9 HCAPLUS
CN Phenol, 4-[3-[2-(6-amino-3-pyridinyl)-4-morpholinyl]butyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 7 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 140690-78-4 HCAPLUS
CN 2-Pyridinamine, 5-[4-[2-(5-methoxy-1H-indol-3-yl)-1-methylethyl]-2-morpholinyl]- (9CI) (CA INDEX NAME)



RN 140690-79-5 HCAPLUS
CN 1H-Indol-5-ol, 3-[2-[2-(6-amino-3-pyridinyl)-4-morpholinyl]propyl]- (9CI) (CA INDEX NAME)



RN 141137-41-9 HCAPLUS
CN 2-Pyridinamine, 5-[4-(1,1-dimethylpropyl)-2-morpholinyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 5 OF 7 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 140690-74-0 HCAPLUS
CN 2-Pyridinamine, 5-[4-[2-(1H-indol-3-yl)-1-methylethyl]-2-morpholinyl]- (9CI) (CA INDEX NAME)



RN 140690-75-1 HCAPLUS
CN 2-Pyridinamine, 5-[4-[2-(1H-indol-3-yl)-1,1-dimethylethyl]-2-morpholinyl]- (9CI) (CA INDEX NAME)



RN 140690-76-2 HCAPLUS
CN 2-Pyridinamine, 5-[4-[2-(5-methoxy-1H-indol-3-yl)-1,1-dimethylethyl]-2-morpholinyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 6 OF 7 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 12 May 1990
GI For diagram(s), see printed CA Issue.
AB The title compds. [I; R1 = (halo-, CF3-, or alkyl-substituted) heteroaryl; R2 = H, OH; R3 = OH, CO2H, alkoxycarbonyl, carbamoyl, (substituted) alkoxy, vinyl; A = (Me- or Et-substituted) C2-3 alkylene; X = bond, O; n = 0, 1], useful as platelet aggregation inhibitors, antidiabetics, antiobesity agents, antihyperlipoproteinemics, and anabolic agents, were prepared Thus, 2-(6-chloropyridin-2-yl)morpholine and 1-(4-carbomethoxymethoxyphenyl)propan-2-one in MeOH were stirred with HOAc and NaBH3CN to give 84% II. II at 0.3 mg/kg orally in mice reduced blood glucose by 50% and increased blood glycerin by 262%. Numerous formulations of I were given.

ACCESSION NUMBER: 1990:178999 HCAPLUS
DOCUMENT NUMBER: 112:178999
TITLE: Morpholines and morpholine N-oxides, medicines containing these compounds and process for their preparation
INVENTOR(S): Reiffen, Manfred; Mark, Michael; Sauter, Robert; Grell, Wolfgang
PATENT ASSIGNEE(S): Thomae, Dr. Karl, G.m.b.H., Fed. Rep. Ger.
SOURCE: Eur. Pat. Appl., 28 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 334146	A1	19890927	EP 1989-104376	19890313
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
DE 3809775	A1	19891005	DE 1988-3809775	19880323
JP 01299287	A2	19891204	JP 1989-70300	19890322
US 5026702	A	19910625	US 1989-327665	19890323
PRIORITY APPLN. INFO.:			DE 1988-3809775 A	19880323

OTHER SOURCE(S): CASREACT 112:178999; MARPAT 112:178999
IT 126325-24-4P 126325-25-5P 126325-29-9P 126325-39-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as drug)
RN 126325-24-4 HCAPLUS
CN Acetic acid, [4-[2-[2-(5-bromo-3-pyridinyl)-2-hydroxy-4-morpholinyl]propyl]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 7 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 126325-25-5 HCAPLUS
CN Acetic acid, [4-[2-[2-(5-bromo-3-pyridinyl)-2-hydroxy-4-morpholinyl]propyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 126325-29-9 HCAPLUS
CN Acetic acid, [4-[2-[2-(3-pyridinyl)-4-morpholinyl]propyl]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 7 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 126325-39-1 HCAPLUS
CN Acetic acid, [4-[2-[2-(3-pyridinyl)-4-morpholinyl]propyl]phenoxy]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L4 ANSWER 7 OF 7 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 12 May 1984
GI



AB Title compds. I [n = 1, 2, 3; R = alkyl, cyclohexyl, Ph, halo-, methyl-, methoxy-, hydroxy-, cyano-, nitro-, (trifluoromethyl)-, carboxy-, carbethoxy-, acetamido-, (methylsulfonyl)-, phenoxy-, benzoyl-, (α-hydroxybenzyl)-, cyclohexyl-, or carbamoylphenyl, biphenylyl, thienyl, pyridyl, naphthyl, adamantyl, PhCH2; R1 = H, alkyl, cyclohexyl, PhCH2] were prepared by different methods. A mixture of II, 4-MeC6H4SO3H, C6H6, and water was refluxed to give I (n = 1, R = CMe3, R1 = PhCH2) (III). III.HCl exhibited analgesic activity, ED50 18 mg/kg/i.p., in mice.

ACCESSION NUMBER: 1983:72148 HCAPLUS
DOCUMENT NUMBER: 98:72148
TITLE: Dioxabicyclic derivatives and their therapeutic use
PATENT ASSIGNEE(S): Delalande S. A. , Fr.
SOURCE: Belg., 34 pp.
CODEN: BEXXAL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
BE 892853	A1	19821015	BE 1982-207826	19820415
FR 2504141	A1	19821022	FR 1981-7904	19810421
FR 2504141	B1	19831230		
FR 2524469	A2	19831007	FR 1982-5553	19820331
FR 2524469	B2	19840629		
SE 8202364	A	19821022	SE 1982-2364	19820415
GB 2096998	A	19821027	GB 1982-11124	19820416
GB 2096998	B2	19850424		
US 4463004	A	19840731	US 1982-368924	19820416
ZA 8202639	A	19830330	ZA 1982-2639	19820419
AU 8282845	A1	19821028	AU 1982-82845	19820420
NL 8201642	A	19821116	NL 1982-1642	19820420
JP 57188593	A2	19821119	JP 1982-64723	19820420
DE 3214570	A1	19821230	DE 1982-3214570	19820420
ES 512108	A1	19830701	ES 1982-512108	19820420

PRIORITY APPLN. INFO.: FR 1981-7904 A 19810421
FR 1982-5553 A 19820331

OTHER SOURCE(S): CASREACT 98:72148
IT 84508-84-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and cyclocondensation of)
RN 84508-84-9 HCAPLUS
CN 2-Morpholinemethanol, 6-hydroxy-4-(phenylmethyl)-6-(3-pyridinyl)-, α-(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 7 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT 84508-85-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and selective O-tosylation of)
RN 84508-85-0 HCAPLUS
CN 2-Morpholinemethanol, 6-hydroxy-4-(phenylmethyl)-6-(3-pyridinyl)- (9CI) (CA INDEX NAME)



IT 84508-83-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 84508-83-8 HCAPLUS
CN 6,8-Dioxa-3-azabicyclo[3.2.1]octane, 3-(phenylmethyl)-5-(3-pyridinyl)- (9CI) (CA INDEX NAME)



```
=> logy
LOGY IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    37.03     198.57

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -5.11      -5.11

STN INTERNATIONAL LOGOFF AT 11:22:19 ON 21 DEC 2005
```